Marilou Linatoc
Nurse Practitioner · Albuquerque, NMNPI 1679506349
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 215 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$733
- Lilly USA, LLC$672
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$421
- Amgen$246
- AstraZeneca$201
- Novo Nordisk$180
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,571100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $733 |
| Lilly USA, LLC | 44 | $672 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $421 |
| Amgen | 13 | $246 |
| AstraZeneca | 12 | $201 |
| Novo Nordisk | 10 | $180 |
| Merck | 11 | $173 |
| Pfizer | 8 | $136 |
| Novartis | 6 | $126 |
| Exact Sciences | 6 | $106 |
| Biohaven Pharmaceuticals, Inc. | 4 | $89 |
| Abbott | 4 | $71 |
| Revance Therapeutics, Inc. | 1 | $58 |
| Johnson & Johnson | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| Boehringer Ingelheim | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Lundbeck LLC | 1 | $26 |
| Boston Scientific | 1 | $25 |
| Angiodynamics, Inc. | 1 | $22 |
| Medline Industries LP | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Axonics, Inc. | 1 | $19 |
| Medtronic | 1 | $15 |
How this compares
$3,571 in reported general payments places this provider in the 95th percentile of 624 nurse practitioner providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $116,332 |
| MounjaroTirzepatide | 53 | $66,680 |
| TrulicityDulaglutide | 44 | $55,460 |
| JardianceEmpagliflozin | 34 | $49,207 |
| EliquisApixaban | 25 | $27,659 |
| LinzessLinaclotide | 13 | $20,269 |
| FarxigaDapagliflozin Propanediol | 17 | $16,060 |
| XareltoRivaroxaban | 15 | $12,590 |
| JanuviaSitagliptin Phosphate | 18 | $12,311 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,708 |
| Lisinopril | 182 | $1,941 |
| Rosuvastatin Calcium | 162 | $1,920 |
| ProgesteroneProgesterone, Micronized | 39 | $1,730 |
| Atorvastatin Calcium | 115 | $1,604 |
| Losartan Potassium | 113 | $1,513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $672 | $122,14097 claims |
| Novo NordiskOzempic | $180 | $116,33296 claims |
| Boehringer IngelheimJardiance | $44 | $49,20734 claims |
| PfizerEliquis | $136 | $27,65925 claims |
| AbbVieLinzess | $733 | $20,26913 claims |
| AstraZenecaFarxiga | $201 | $16,06017 claims |
| Johnson & JohnsonXarelto | $55 | $12,59015 claims |
| MerckJanuvia | $173 | $12,31118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 nurse practitioner providers in New Mexico.
Other nurse practitioner in Albuquerque
- Marisa EscobarAlbuquerque$36K
- Catherine SollerAlbuquerque$33K
- Christina ParksAlbuquerque$7K
- Paula JohnsonAlbuquerque$6K
- Nadia Cano VazquezAlbuquerque$6K
- Laura LeblancAlbuquerque$6K
- Dina KotovaAlbuquerque$6K
- Alisha LowdenAlbuquerque$5K
- Lizette Sidransky-UlloaAlbuquerque$5K
- Mary TrujilloAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.